Oxymetazoline hydrochloride Cream, 1% + Rhofade™ (oxymetazoline) cream, 1% + Placebo
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bioequivalence
Conditions
Bioequivalence
Trial Timeline
Feb 23, 2018 → May 31, 2019
NCT ID
NCT05148689About Oxymetazoline hydrochloride Cream, 1% + Rhofade™ (oxymetazoline) cream, 1% + Placebo
Oxymetazoline hydrochloride Cream, 1% + Rhofade™ (oxymetazoline) cream, 1% + Placebo is a phase 1 stage product being developed by Sun Pharmaceutical for Bioequivalence. The current trial status is completed. This product is registered under clinical trial identifier NCT05148689. Target conditions include Bioequivalence.
What happened to similar drugs?
1 of 1 similar drugs in Bioequivalence were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05148689 | Phase 1 | Completed |
Competing Products
20 competing products in Bioequivalence